248 related articles for article (PubMed ID: 22984227)
1. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.
Tovar-y-Romo LB; Bumpus NN; Pomerantz D; Avery LB; Sacktor N; McArthur JC; Haughey NJ
J Pharmacol Exp Ther; 2012 Dec; 343(3):696-703. PubMed ID: 22984227
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
3. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
Avery LB; Sacktor N; McArthur JC; Hendrix CW
Antimicrob Agents Chemother; 2013 Mar; 57(3):1409-14. PubMed ID: 23295919
[TBL] [Abstract][Full Text] [Related]
4. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects.
Ranzani A; Castelli F; Di Biagio A; d'Arminio Monforte A; D'Avolio A; Soria A; Bai F; Focà E; Taramasso L; Calcagno A; Bresciani E; Torsello A; Bonfanti P; Lapadula G
HIV Med; 2024 Apr; 25(4):491-497. PubMed ID: 38104964
[TBL] [Abstract][Full Text] [Related]
5. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
Avery LB; VanAusdall JL; Hendrix CW; Bumpus NN
Drug Metab Dispos; 2013 Feb; 41(2):422-9. PubMed ID: 23166317
[TBL] [Abstract][Full Text] [Related]
6. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
Brown TT; McComsey GA
Antivir Ther; 2010; 15(3):425-9. PubMed ID: 20516561
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
Best BM; Koopmans PP; Letendre SL; Capparelli EV; Rossi SS; Clifford DB; Collier AC; Gelman BB; Mbeo G; McCutchan JA; Simpson DM; Haubrich R; Ellis R; Grant I;
J Antimicrob Chemother; 2011 Feb; 66(2):354-7. PubMed ID: 21098541
[TBL] [Abstract][Full Text] [Related]
8. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.
Huang SH; Huang WC; Lin SW; Chuang YC; Sun HY; Chang SY; Kuo PH; Wu PY; Liu WC; Chiang C; Hung CC; Chang SC
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):834-841. PubMed ID: 33587507
[TBL] [Abstract][Full Text] [Related]
9. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
Takahashi M; Ibe S; Kudaka Y; Okumura N; Hirano A; Suzuki T; Mamiya N; Hamaguchi M; Kaneda T
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):983-7. PubMed ID: 17725414
[TBL] [Abstract][Full Text] [Related]
10. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J; Fayet A; Arab-Alameddine M; Rotger M; Lubomirov R; Cavassini M; Furrer H; Günthard HF; Colombo S; Csajka C; Eap CB; Decosterd LA; Telenti A;
Pharmacogenet Genomics; 2009 Apr; 19(4):300-9. PubMed ID: 19238117
[TBL] [Abstract][Full Text] [Related]
11. The male genital tract is not a pharmacological sanctuary from efavirenz.
Avery LB; Bakshi RP; Cao YJ; Hendrix CW
Clin Pharmacol Ther; 2011 Jul; 90(1):151-6. PubMed ID: 21633344
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
13. The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro.
Mast N; Fotinich A; Pikuleva IA
Drug Metab Dispos; 2022 Jul; 50(7):923-930. PubMed ID: 35489779
[TBL] [Abstract][Full Text] [Related]
14. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C
Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252
[TBL] [Abstract][Full Text] [Related]
15. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA;
Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510
[TBL] [Abstract][Full Text] [Related]
16. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
[TBL] [Abstract][Full Text] [Related]
17. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells.
Apostolova N; Gomez-Sucerquia LJ; Moran A; Alvarez A; Blas-Garcia A; Esplugues JV
Br J Pharmacol; 2010 Aug; 160(8):2069-84. PubMed ID: 20649602
[TBL] [Abstract][Full Text] [Related]
18. A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry.
Amara AB; Else LJ; Tjia J; Olagunju A; Puls RL; Khoo S; Back DJ
Ther Drug Monit; 2015 Apr; 37(2):220-8. PubMed ID: 25162217
[TBL] [Abstract][Full Text] [Related]
19. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
